They revealed that continued sorafenib exposure induces a hypoxic microenvironment that activates HIF-1α and NF-κB pathways, leading to the development of resistance in HCC (Liang et al., 2013). The gene discussed is NFKB1; the disease is hepatocellular carcinoma.